APO Research
Talk to an analyst

APO RESEARCH · REPORT

Long-acting Anti-HIV Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Long-acting Anti-HIV Drugs Market Outlook and Growth Opportunities 2026

29 December 2025199 pages

Choose your research edition.

Industry ResearchLong-acting Anti-HIV Drugs Industry Research Report 2026107 pages · $2,950 USDIndustry Growth & TrendsGlobal Long-acting Anti-HIV Drugs Industry Growth and Trends Forecast to 203271 pages · $3,450 USDMarket StructureGlobal Long-acting Anti-HIV Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032170 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Long-acting Anti-HIV Drugs Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Long-acting Anti-HIV Drugs Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Long-acting Anti-HIV Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Long-acting Anti-HIV Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Long-acting Anti-HIV Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Long-acting Anti-HIV Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Long-acting Anti-HIV Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Long-acting Anti-HIV Drugs market include Theratechnologies, ViiV Healthcare, Gilead Sciences and Janssen Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Long-acting Anti-HIV Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Long-acting Anti-HIV Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Long-acting Anti-HIV Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Long-acting Anti-HIV Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Long-acting Anti-HIV Drugs Segment by Company

Theratechnologies

ViiV Healthcare

Gilead Sciences

Janssen Pharmaceuticals

Long-acting Anti-HIV Drugs Segment by Type

Single Drug

Combination Preparation

Long-acting Anti-HIV Drugs Segment by Application

HIV Prevention

HIV Treatment

Long-acting Anti-HIV Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Long-acting Anti-HIV Drugs status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Long-acting Anti-HIV Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Long-acting Anti-HIV Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze Long-acting Anti-HIV Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Long-acting Anti-HIV Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Long-acting Anti-HIV Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Long-acting Anti-HIV Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Long-acting Anti-HIV Drugs market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Long-acting Anti-HIV Drugs industry.

Chapter 3: Detailed analysis of Long-acting Anti-HIV Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Long-acting Anti-HIV Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Long-acting Anti-HIV Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Long-acting Anti-HIV Drugs Industry Trends Table 2. Long-acting Anti-HIV Drugs Industry Drivers Table 3. Long-acting Anti-HIV Drugs Industry Opportunities and Challenges Table 4. Long-acting Anti-HIV Drugs Industry Restraints Table 5. Global Long-acting Anti-HIV Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Long-acting Anti-HIV Drugs Revenue Share by Company (2021-2026) Table 7. Global Long-acting Anti-HIV Drugs Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Long-acting Anti-HIV Drugs Sales Volume Share by Company (2021-2026) Table 9. Global Long-acting Anti-HIV Drugs Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Long-acting Anti-HIV Drugs Company Ranking, (2024-2026) & (USD Million) Table 11. Global Long-acting Anti-HIV Drugs Key Company Manufacturing Base & Headquarters Table 12. Global Long-acting Anti-HIV Drugs Company, Product Type & Application Table 13. Global Long-acting Anti-HIV Drugs Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Long-acting Anti-HIV Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Single Drug Table 18. Significant Companies of Combination Preparation Table 19. Global Long-acting Anti-HIV Drugs Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global Long-acting Anti-HIV Drugs Sales Volume by Type (2021-2026) & (K Units) Table 21. Global Long-acting Anti-HIV Drugs Sales Volume by Type (2027-2032) & (K Units) Table 22. Global Long-acting Anti-HIV Drugs Sales Volume Share by Type (2021-2026) Table 23. Global Long-acting Anti-HIV Drugs Sales Volume Share by Type (2027-2032) Table 24. Global Long-acting Anti-HIV Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Long-acting Anti-HIV Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Long-acting Anti-HIV Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Long-acting Anti-HIV Drugs Sales Value Share by Type (2021-2026) Table 28. Global Long-acting Anti-HIV Drugs Sales Value Share by Type (2027-2032) Table 29. Significant Companies of HIV Prevention Table 30. Significant Companies of HIV Treatment Table 31. Global Long-acting Anti-HIV Drugs Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 32. Global Long-acting Anti-HIV Drugs Sales Volume by Application (2021-2026) & (K Units) Table 33. Global Long-acting Anti-HIV Drugs Sales Volume by Application (2027-2032) & (K Units) Table 34. Global Long-acting Anti-HIV Drugs Sales Volume Share by Application (2021-2026) Table 35. Global Long-acting Anti-HIV Drugs Sales Volume Share by Application (2027-2032) Table 36. Global Long-acting Anti-HIV Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Long-acting Anti-HIV Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 38. Global Long-acting Anti-HIV Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 39. Global Long-acting Anti-HIV Drugs Sales Value Share by Application (2021-2026) Table 40. Global Long-acting Anti-HIV Drugs Sales Value Share by Application (2027-2032) Table 41. Global Long-acting Anti-HIV Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 42. Global Long-acting Anti-HIV Drugs Sales by Region (2021-2026) & (K Units) Table 43. Global Long-acting Anti-HIV Drugs Sales Market Share by Region (2021-2026) Table 44. Global Long-acting Anti-HIV Drugs Sales by Region (2027-2032) & (K Units) Table 45. Global Long-acting Anti-HIV Drugs Sales Market Share by Region (2027-2032) Table 46. Global Long-acting Anti-HIV Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 47. Global Long-acting Anti-HIV Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 48. Global Long-acting Anti-HIV Drugs Sales Value Share by Region (2021-2026) Table 49. Global Long-acting Anti-HIV Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 50. Global Long-acting Anti-HIV Drugs Sales Value Share by Region (2027-2032) Table 51. Global Long-acting Anti-HIV Drugs Market Average Price (US$/Unit) by Region (2021-2026) Table 52. Global Long-acting Anti-HIV Drugs Market Average Price (US$/Unit) by Region (2027-2032) Table 53. Global Long-acting Anti-HIV Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 54. Global Long-acting Anti-HIV Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 55. Global Long-acting Anti-HIV Drugs Sales by Country (2021-2026) & (K Units) Table 56. Global Long-acting Anti-HIV Drugs Sales Market Share by Country (2021-2026) Table 57. Global Long-acting Anti-HIV Drugs Sales by Country (2027-2032) & (K Units) Table 58. Global Long-acting Anti-HIV Drugs Sales Market Share by Country (2027-2032) Table 59. Global Long-acting Anti-HIV Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 60. Global Long-acting Anti-HIV Drugs Sales Value Market Share by Country (2021-2026) Table 61. Global Long-acting Anti-HIV Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 62. Global Long-acting Anti-HIV Drugs Sales Value Market Share by Country (2027-2032) Table 63. Theratechnologies Company Information Table 64. Theratechnologies Business Overview Table 65. Theratechnologies Long-acting Anti-HIV Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. Theratechnologies Long-acting Anti-HIV Drugs Product Portfolio Table 67. Theratechnologies Recent Development Table 68. ViiV Healthcare Company Information Table 69. ViiV Healthcare Business Overview Table 70. ViiV Healthcare Long-acting Anti-HIV Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. ViiV Healthcare Long-acting Anti-HIV Drugs Product Portfolio Table 72. ViiV Healthcare Recent Development Table 73. Gilead Sciences Company Information Table 74. Gilead Sciences Business Overview Table 75. Gilead Sciences Long-acting Anti-HIV Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Gilead Sciences Long-acting Anti-HIV Drugs Product Portfolio Table 77. Gilead Sciences Recent Development Table 78. Janssen Pharmaceuticals Company Information Table 79. Janssen Pharmaceuticals Business Overview Table 80. Janssen Pharmaceuticals Long-acting Anti-HIV Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Janssen Pharmaceuticals Long-acting Anti-HIV Drugs Product Portfolio Table 82. Janssen Pharmaceuticals Recent Development Table 83. Key Raw Materials Table 84. Raw Materials Key Suppliers Table 85. Long-acting Anti-HIV Drugs Distributors List Table 86. Long-acting Anti-HIV Drugs Customers List Table 87. Research Programs/Design for This Report Table 88. Authors List of This Report Table 89. Secondary Sources Table 90. Primary Sources List of Figures Figure 1. Long-acting Anti-HIV Drugs Product Image Figure 2. Global Long-acting Anti-HIV Drugs Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Long-acting Anti-HIV Drugs Sales Value (2021-2032) & (US$ Million) Figure 4. Global Long-acting Anti-HIV Drugs Sales (2021-2032) & (K Units) Figure 5. Global Long-acting Anti-HIV Drugs Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Long-acting Anti-HIV Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Single Drug Image Figure 10. Combination Preparation Image Figure 11. Global Long-acting Anti-HIV Drugs Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global Long-acting Anti-HIV Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Long-acting Anti-HIV Drugs Sales Volume Share by Type (2021-2032) Figure 14. Global Long-acting Anti-HIV Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Long-acting Anti-HIV Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Long-acting Anti-HIV Drugs Sales Value Share by Type (2021-2032) Figure 17. HIV Prevention Image Figure 18. HIV Treatment Image Figure 19. Global Long-acting Anti-HIV Drugs Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 20. Global Long-acting Anti-HIV Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 21. Global Long-acting Anti-HIV Drugs Sales Volume Share by Application (2021-2032) Figure 22. Global Long-acting Anti-HIV Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Long-acting Anti-HIV Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 24. Global Long-acting Anti-HIV Drugs Sales Value Share by Application (2021-2032) Figure 25. Global Long-acting Anti-HIV Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 26. Global Long-acting Anti-HIV Drugs Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 27. Global Long-acting Anti-HIV Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 28. Global Long-acting Anti-HIV Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 29. North America Long-acting Anti-HIV Drugs Sales Value (2021-2032) & (US$ Million) Figure 30. North America Long-acting Anti-HIV Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Europe Long-acting Anti-HIV Drugs Sales Value (2021-2032) & (US$ Million) Figure 32. Europe Long-acting Anti-HIV Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Asia-Pacific Long-acting Anti-HIV Drugs Sales Value (2021-2032) & (US$ Million) Figure 34. Asia-Pacific Long-acting Anti-HIV Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 35. South America Long-acting Anti-HIV Drugs Sales Value (2021-2032) & (US$ Million) Figure 36. South America Long-acting Anti-HIV Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Middle East & Africa Long-acting Anti-HIV Drugs Sales Value (2021-2032) & (US$ Million) Figure 38. Middle East & Africa Long-acting Anti-HIV Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 39. USA Long-acting Anti-HIV Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. USA Long-acting Anti-HIV Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. USA Long-acting Anti-HIV Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Canada Long-acting Anti-HIV Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Canada Long-acting Anti-HIV Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Canada Long-acting Anti-HIV Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Mexico Long-acting Anti-HIV Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Mexico Long-acting Anti-HIV Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Mexico Long-acting Anti-HIV Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Germany Long-acting Anti-HIV Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Germany Long-acting Anti-HIV Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Germany Long-acting Anti-HIV Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. France Long-acting Anti-HIV Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. France Long-acting Anti-HIV Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. France Long-acting Anti-HIV Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. U.K. Long-acting Anti-HIV Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. U.K. Long-acting Anti-HIV Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. U.K. Long-acting Anti-HIV Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Italy Long-acting Anti-HIV Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Italy Long-acting Anti-HIV Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Italy Long-acting Anti-HIV Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Spain Long-acting Anti-HIV Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Spain Long-acting Anti-HIV Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Spain Long-acting Anti-HIV Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Russia Long-acting Anti-HIV Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Russia Long-acting Anti-HIV Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Russia Long-acting Anti-HIV Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Netherlands Long-acting Anti-HIV Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Netherlands Long-acting Anti-HIV Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Netherlands Long-acting Anti-HIV Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Nordic Countries Long-acting Anti-HIV Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Nordic Countries Long-acting Anti-HIV Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Nordic Countries Long-acting Anti-HIV Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. China Long-acting Anti-HIV Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. China Long-acting Anti-HIV Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. China Long-acting Anti-HIV Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Japan Long-acting Anti-HIV Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Japan Long-acting Anti-HIV Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Japan Long-acting Anti-HIV Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. South Korea Long-acting Anti-HIV Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. South Korea Long-acting Anti-HIV Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. South Korea Long-acting Anti-HIV Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. India Long-acting Anti-HIV Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. India Long-acting Anti-HIV Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. India Long-acting Anti-HIV Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Australia Long-acting Anti-HIV Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Australia Long-acting Anti-HIV Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Australia Long-acting Anti-HIV Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Southeast Asia Long-acting Anti-HIV Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Southeast Asia Long-acting Anti-HIV Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Southeast Asia Long-acting Anti-HIV Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Brazil Long-acting Anti-HIV Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Brazil Long-acting Anti-HIV Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Brazil Long-acting Anti-HIV Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Argentina Long-acting Anti-HIV Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Argentina Long-acting Anti-HIV Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Argentina Long-acting Anti-HIV Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Chile Long-acting Anti-HIV Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Chile Long-acting Anti-HIV Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Chile Long-acting Anti-HIV Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Colombia Long-acting Anti-HIV Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Colombia Long-acting Anti-HIV Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Colombia Long-acting Anti-HIV Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Peru Long-acting Anti-HIV Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Peru Long-acting Anti-HIV Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Peru Long-acting Anti-HIV Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Saudi Arabia Long-acting Anti-HIV Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Saudi Arabia Long-acting Anti-HIV Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Long-acting Anti-HIV Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Israel Long-acting Anti-HIV Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Israel Arabia Long-acting Anti-HIV Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Israel Arabia Long-acting Anti-HIV Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. UAE Long-acting Anti-HIV Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. UAE Long-acting Anti-HIV Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. UAE Long-acting Anti-HIV Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Turkey Long-acting Anti-HIV Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Turkey Long-acting Anti-HIV Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Turkey Long-acting Anti-HIV Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Iran Long-acting Anti-HIV Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Iran Long-acting Anti-HIV Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Iran Long-acting Anti-HIV Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Egypt Long-acting Anti-HIV Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Egypt Long-acting Anti-HIV Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Egypt Long-acting Anti-HIV Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Long-acting Anti-HIV Drugs Value Chain Figure 124. Manufacturing Cost Structure Figure 125. Long-acting Anti-HIV Drugs Sales Mode & Process Figure 126. Direct Comparison with Distribution Share Figure 127. Distributors Profiles Figure 128. Years Considered Figure 129. Research Process Figure 130. Key Executives Interviewed

Scope & coverage.

Types
  • Single Drug
  • Combination Preparation
Applications
  • HIV Prevention
  • HIV Treatment
Companies covered
  • Theratechnologies
  • ViiV Healthcare
  • Gilead Sciences
  • Janssen Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Long-acting Anti-HIV Drugs Sales Value (2021-2032)
  4. 1.2.2 Global Long-acting Anti-HIV Drugs Sales Volume (2021-2032)
  5. 1.2.3 Global Long-acting Anti-HIV Drugs Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Long-acting Anti-HIV Drugs Market Dynamics
  1. 2.1 Long-acting Anti-HIV Drugs Industry Trends
  2. 2.2 Long-acting Anti-HIV Drugs Industry Drivers
  3. 2.3 Long-acting Anti-HIV Drugs Industry Opportunities and Challenges
  4. 2.4 Long-acting Anti-HIV Drugs Industry Restraints
3 Long-acting Anti-HIV Drugs Market by Company
  1. 3.1 Global Long-acting Anti-HIV Drugs Company Revenue Ranking in 2025
  2. 3.2 Global Long-acting Anti-HIV Drugs Revenue by Company (2021-2026)
  3. 3.3 Global Long-acting Anti-HIV Drugs Sales Volume by Company (2021-2026)
  4. 3.4 Global Long-acting Anti-HIV Drugs Average Price by Company (2021-2026)
  5. 3.5 Global Long-acting Anti-HIV Drugs Company Ranking (2024-2026)
  6. 3.6 Global Long-acting Anti-HIV Drugs Company Manufacturing Base and Headquarters
  7. 3.7 Global Long-acting Anti-HIV Drugs Company Product Type and Application
  8. 3.8 Global Long-acting Anti-HIV Drugs Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Long-acting Anti-HIV Drugs Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Long-acting Anti-HIV Drugs Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Long-acting Anti-HIV Drugs Market by Type
  1. 4.1 Long-acting Anti-HIV Drugs Type Introduction
  2. 4.1.1 Single Drug
  3. 4.1.2 Combination Preparation
  4. 4.2 Global Long-acting Anti-HIV Drugs Sales Volume by Type
  5. 4.2.1 Global Long-acting Anti-HIV Drugs Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Long-acting Anti-HIV Drugs Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Long-acting Anti-HIV Drugs Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Long-acting Anti-HIV Drugs Sales Value by Type
  9. 4.3.1 Global Long-acting Anti-HIV Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Long-acting Anti-HIV Drugs Sales Value by Type (2021-2032)
  11. 4.3.3 Global Long-acting Anti-HIV Drugs Sales Value Share by Type (2021-2032)
5 Long-acting Anti-HIV Drugs Market by Application
  1. 5.1 Long-acting Anti-HIV Drugs Application Introduction
  2. 5.1.1 HIV Prevention
  3. 5.1.2 HIV Treatment
  4. 5.2 Global Long-acting Anti-HIV Drugs Sales Volume by Application
  5. 5.2.1 Global Long-acting Anti-HIV Drugs Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Long-acting Anti-HIV Drugs Sales Volume by Application (2021-2032)
  7. 5.2.3 Global Long-acting Anti-HIV Drugs Sales Volume Share by Application (2021-2032)
  8. 5.3 Global Long-acting Anti-HIV Drugs Sales Value by Application
  9. 5.3.1 Global Long-acting Anti-HIV Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Long-acting Anti-HIV Drugs Sales Value by Application (2021-2032)
  11. 5.3.3 Global Long-acting Anti-HIV Drugs Sales Value Share by Application (2021-2032)
6 Long-acting Anti-HIV Drugs Regional Sales and Value Analysis
  1. 6.1 Global Long-acting Anti-HIV Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Long-acting Anti-HIV Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Long-acting Anti-HIV Drugs Sales by Region: 2021-2026
  4. 6.2.2 Global Long-acting Anti-HIV Drugs Sales by Region (2027-2032)
  5. 6.3 Global Long-acting Anti-HIV Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Long-acting Anti-HIV Drugs Sales Value by Region (2021-2032)
  7. 6.4.1 Global Long-acting Anti-HIV Drugs Sales Value by Region: 2021-2026
  8. 6.4.2 Global Long-acting Anti-HIV Drugs Sales Value by Region (2027-2032)
  9. 6.5 Global Long-acting Anti-HIV Drugs Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Long-acting Anti-HIV Drugs Sales Value (2021-2032)
  12. 6.6.2 North America Long-acting Anti-HIV Drugs Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Long-acting Anti-HIV Drugs Sales Value (2021-2032)
  15. 6.7.2 Europe Long-acting Anti-HIV Drugs Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Long-acting Anti-HIV Drugs Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Long-acting Anti-HIV Drugs Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Long-acting Anti-HIV Drugs Sales Value (2021-2032)
  21. 6.9.2 South America Long-acting Anti-HIV Drugs Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Long-acting Anti-HIV Drugs Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Long-acting Anti-HIV Drugs Sales Value Share by Country, 2025 VS 2032
7 Long-acting Anti-HIV Drugs Country-level Sales and Value Analysis
  1. 7.1 Global Long-acting Anti-HIV Drugs Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Long-acting Anti-HIV Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Long-acting Anti-HIV Drugs Sales by Country (2021-2032)
  4. 7.3.1 Global Long-acting Anti-HIV Drugs Sales by Country (2021-2026)
  5. 7.3.2 Global Long-acting Anti-HIV Drugs Sales by Country (2027-2032)
  6. 7.4 Global Long-acting Anti-HIV Drugs Sales Value by Country (2021-2032)
  7. 7.4.1 Global Long-acting Anti-HIV Drugs Sales Value by Country (2021-2026)
  8. 7.4.2 Global Long-acting Anti-HIV Drugs Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Long-acting Anti-HIV Drugs Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Long-acting Anti-HIV Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Long-acting Anti-HIV Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Long-acting Anti-HIV Drugs Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Long-acting Anti-HIV Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Long-acting Anti-HIV Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Long-acting Anti-HIV Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Long-acting Anti-HIV Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Long-acting Anti-HIV Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Long-acting Anti-HIV Drugs Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Long-acting Anti-HIV Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Long-acting Anti-HIV Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Long-acting Anti-HIV Drugs Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Long-acting Anti-HIV Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Long-acting Anti-HIV Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Long-acting Anti-HIV Drugs Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Long-acting Anti-HIV Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Long-acting Anti-HIV Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Long-acting Anti-HIV Drugs Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Long-acting Anti-HIV Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Long-acting Anti-HIV Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Long-acting Anti-HIV Drugs Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Long-acting Anti-HIV Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Long-acting Anti-HIV Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Long-acting Anti-HIV Drugs Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Long-acting Anti-HIV Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Long-acting Anti-HIV Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Long-acting Anti-HIV Drugs Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Long-acting Anti-HIV Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Long-acting Anti-HIV Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Long-acting Anti-HIV Drugs Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Long-acting Anti-HIV Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Long-acting Anti-HIV Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Long-acting Anti-HIV Drugs Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Long-acting Anti-HIV Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Long-acting Anti-HIV Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Long-acting Anti-HIV Drugs Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Long-acting Anti-HIV Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Long-acting Anti-HIV Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Long-acting Anti-HIV Drugs Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Long-acting Anti-HIV Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Long-acting Anti-HIV Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Long-acting Anti-HIV Drugs Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Long-acting Anti-HIV Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Long-acting Anti-HIV Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Long-acting Anti-HIV Drugs Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Long-acting Anti-HIV Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Long-acting Anti-HIV Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Long-acting Anti-HIV Drugs Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Long-acting Anti-HIV Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Long-acting Anti-HIV Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Long-acting Anti-HIV Drugs Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Long-acting Anti-HIV Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Long-acting Anti-HIV Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Long-acting Anti-HIV Drugs Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Long-acting Anti-HIV Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Long-acting Anti-HIV Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Long-acting Anti-HIV Drugs Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Long-acting Anti-HIV Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Long-acting Anti-HIV Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Long-acting Anti-HIV Drugs Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Long-acting Anti-HIV Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Long-acting Anti-HIV Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Long-acting Anti-HIV Drugs Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Long-acting Anti-HIV Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Long-acting Anti-HIV Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Long-acting Anti-HIV Drugs Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Long-acting Anti-HIV Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Long-acting Anti-HIV Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Long-acting Anti-HIV Drugs Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Long-acting Anti-HIV Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Long-acting Anti-HIV Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Long-acting Anti-HIV Drugs Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Long-acting Anti-HIV Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Long-acting Anti-HIV Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Long-acting Anti-HIV Drugs Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Long-acting Anti-HIV Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Long-acting Anti-HIV Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Long-acting Anti-HIV Drugs Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Long-acting Anti-HIV Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Long-acting Anti-HIV Drugs Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Long-acting Anti-HIV Drugs Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Long-acting Anti-HIV Drugs Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Long-acting Anti-HIV Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Theratechnologies
  2. 8.1.1 Theratechnologies Company Information
  3. 8.1.2 Theratechnologies Business Overview
  4. 8.1.3 Theratechnologies Long-acting Anti-HIV Drugs Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Theratechnologies Long-acting Anti-HIV Drugs Product Portfolio
  6. 8.1.5 Theratechnologies Recent Developments
  7. 8.2 ViiV Healthcare
  8. 8.2.1 ViiV Healthcare Company Information
  9. 8.2.2 ViiV Healthcare Business Overview
  10. 8.2.3 ViiV Healthcare Long-acting Anti-HIV Drugs Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 ViiV Healthcare Long-acting Anti-HIV Drugs Product Portfolio
  12. 8.2.5 ViiV Healthcare Recent Developments
  13. 8.3 Gilead Sciences
  14. 8.3.1 Gilead Sciences Company Information
  15. 8.3.2 Gilead Sciences Business Overview
  16. 8.3.3 Gilead Sciences Long-acting Anti-HIV Drugs Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Gilead Sciences Long-acting Anti-HIV Drugs Product Portfolio
  18. 8.3.5 Gilead Sciences Recent Developments
  19. 8.4 Janssen Pharmaceuticals
  20. 8.4.1 Janssen Pharmaceuticals Company Information
  21. 8.4.2 Janssen Pharmaceuticals Business Overview
  22. 8.4.3 Janssen Pharmaceuticals Long-acting Anti-HIV Drugs Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Janssen Pharmaceuticals Long-acting Anti-HIV Drugs Product Portfolio
  24. 8.4.5 Janssen Pharmaceuticals Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Long-acting Anti-HIV Drugs Value Chain Analysis
  2. 9.1.1 Long-acting Anti-HIV Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Long-acting Anti-HIV Drugs Sales Mode & Process
  6. 9.2 Long-acting Anti-HIV Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Long-acting Anti-HIV Drugs Distributors
  9. 9.2.3 Long-acting Anti-HIV Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst